Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China

CONCLUSIONS: Toripalimab plus chemotherapy was likely to be the cost-effective first-line option for patients with advanced ESCC compared with chemotherapy alone with the WTP threshold of $38,224 per additional QALY gained from the perspective of the Chinese health-care system.PMID:37855081 | DOI:10.1080/14737167.2023.2270159

Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 19, 2023 Category: Health Management Authors: Shuo Kang Xiaohui Wang Zhenhua Pan Huanlong Liu Source Type: research